Crescent Capital BDC Inc (CCAP) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Crescent Capital BDC Inc stock $18.76, price $9.38, upside +100.0%, quality 64 out of 100. Rating: strongly undervalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $8.46 – $17.08 · fair‑value band $12.90 – $36.51 · the $9.38 price screens below the $18.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Crescent Capital BDC in your weekly email
Every Wednesday you see whether Crescent Capital BDC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Crescent Capital BDC, Inc. is as a business development company is a private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.
Stock analysis
Crescent Capital BDC Inc (CCAP) currently trades at $9.38, while our model-based Fair Value estimate is $18.76, implying the stock looks roughly 50% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $37.69 per share, and 12 of the 12 models we run sit above the $9.38 price.
Bear case: the Asset-Based group reads lowest at $12.84, and 0 of the 12 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $12.90 (bear) to $36.51 (bull), the price of $9.38 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Financial Services sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Crescent Capital BDC Inc reported revenue of $156M in FY2025 versus $81.3M in FY2021, a compound +17.7%/yr. Reported net income was $34.5M in FY2025, compounding −19.9%/yr from FY2021.
Key figures
Market cap $346M Small · P/S ratio 2.10 · EPS (TTM) $−0.0900 · Net margin −2.0% · Return on equity −0.5% · Return on assets (EBIT) 5.0% (5-year average) · Operating margin 78.4% · Revenue (TTM) $156M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −16% fair-value upside, at 100%, CCAP screens cheaper than that median.
Fair Value models
Bear$12.90Fair Value $18.76Bull$36.51
Price $9.38 · Upside +100.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 4 officers or directors bought shares worth $1.1M, most recently on Aug 19, 2026. Buying cluster
SaleFIDELITY & GUARANTY LIFE INSURANCE CO10% owner6× since Aug 24, 2026: 525,000 shares, avg. $10.43$5.5MSep 9, 202610b5-1 plan
BuyHenry ChungPresident, Director2× since May 21, 2026: 7,000 shares, avg. $11.25$78,750Aug 19, 2026
BuyGerhard LombardChief Financial Officer3× since Nov 17, 2025: 5,000 shares, avg. $11.92$59,620Aug 19, 2026
BuyJason BreauxChief Executive Officer, Director5,000 shares at $11.19$55,950May 20, 2026
BuySteven F. StrandbergDirector85,000 shares at $11.28$958,800May 19, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+9.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.4%
Start year 2020 (pandemic). Over 10 years: +90.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+90.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−14.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−14.0%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−14.0% vs −6.6%, slowing
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.117% → 53%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−2.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +0.3% a year for the price and −4.5% for the forecasts.
Compare Crescent Capital BDC Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Asset Management · 587 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Above median
Fair Value upside+100.0% · Top 25%
Profitability
Return on assets2.1% · Below median
Net margin (12 months)−2.0% · Bottom 25%
Operating margin (12 months)78.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)−15.5% · Bottom 25%
Dividend yield (12 months)17.1% · Top 25%
Balance sheet
Debt / equity0.93× · Highest 25%
Valuation Multiplesvs Asset Management median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Crescent Capital BDC Inc Fair Value". https://www.fairvalue-calculator.com/stock/CCAP
Frequently asked questions
Is Crescent Capital BDC Inc (CCAP) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $18.76 versus a price of $9.38, about +100% upside (undervalued).
What is the fair value of CCAP?
Our model-based fair value for Crescent Capital BDC Inc is $18.76 (as of Nov 9, 2026), built from audited fundamentals. The current price: $9.38.
What is the quality score of CCAP?
Crescent Capital BDC Inc has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Crescent Capital BDC Inc (CCAP)?
Our model-based price target is the fair value of $18.76 (as of Nov 9, 2026) from 12 valuation models. Cautious scenario $12.90, optimistic scenario $36.51. It is a calculation from audited fundamentals, not an analyst target.
What is the Crescent Capital BDC Inc stock forecast for 2026?
Our models put fair value at $18.76, about +100% upside versus a price of $9.38 (undervalued). Cautious scenario $12.90, optimistic scenario $36.51. The calculation is refreshed regularly with new filings.
What is the revenue of Crescent Capital BDC Inc (CCAP)?
Crescent Capital BDC Inc reported trailing-twelve-month revenue of about $156M (latest available figure, as of Nov 9, 2026).
What growth is priced into Crescent Capital BDC Inc (CCAP)?
For today's price to be fair in a discounted-cash-flow model, Crescent Capital BDC Inc would have to grow free cash flow by +2.7 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +27.4 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of CCAP use?
Our models discount Crescent Capital BDC Inc at 10.2 %: a base by market capitalisation (small), damped by beta 0.62, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Crescent Capital BDC Inc that is +2.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has Crescent Capital BDC Inc (CCAP) delivered so far?
Over the past 5 years revenue at Crescent Capital BDC Inc grew +27.4 % a year. The price currently implies free-cash-flow growth of +2.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Crescent Capital BDC Inc (CCAP) growing?
The median revenue growth in the sector is +9.2 % a year. That is the yardstick for the growth priced into Crescent Capital BDC Inc (+2.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Crescent Capital BDC Inc (CCAP)?
The free-cash-flow yield on the price is 21.62 %: that much free cash flow Crescent Capital BDC Inc produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Crescent Capital BDC Inc (CCAP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Crescent Capital BDC Inc it is $18.76 per share (as of Nov 9, 2026), against a price of $9.38. It is the blended result of 12 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Crescent Capital BDC Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, CCAP trades below its calculated fair value: price $9.38, fair value $18.76, a gap of about +100% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CCAP?
No. The price is what the market pays today ($9.38); the fair value is what the company's own numbers justify ($18.76). For Crescent Capital BDC Inc the two are $9.38 per share apart. That gap is exactly why we show both numbers side by side.
How much is Crescent Capital BDC Inc worth?
The market values Crescent Capital BDC Inc at about $346M (market capitalisation, as of Nov 9, 2026). Per share that is $9.38; our models calculate a fair value of $18.76 per share.
What do the bullish and bearish scenarios say about CCAP?
Our models span a range for Crescent Capital BDC Inc: cautious scenario $12.90, base $18.76, optimistic $36.51 per share (as of Nov 9, 2026, price $9.38). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of CCAP?
The PEG ratio of Crescent Capital BDC Inc is 0.89 (P/E divided by earnings growth, as of Nov 9, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Crescent Capital BDC Inc (CCAP)?
Balance-sheet figures for Crescent Capital BDC Inc (as of Nov 9, 2026): return on equity −0.5%, debt of 0.93 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is CCAP from its 52-week high?
Crescent Capital BDC Inc trades at $9.38, about 34% below its 52-week high of $14.31 and 10% above the low of $8.50 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $18.76 is for.
Which stocks are comparable to Crescent Capital BDC Inc?
From the same area (Financial Services) we also value Blackstone Inc, Brookfield Asset Management Ltd, KKR & Co, Apollo Global Management, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Crescent Capital BDC Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $9.38, calculated fair value $18.76 (+100%), Quality Score 64/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CCAP calculated?
We run Crescent Capital BDC Inc through 12 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $18.76 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Crescent Capital BDC Inc currently trades 50% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Crescent Capital BDC Inc (CCAP)?
The closing price on Nov 6, 2026 was $9.38. Our model-based fair value is $18.76, about +100% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Crescent Capital BDC Inc right now?
The price is below even our cautious bear case ($12.90). The market is more pessimistic than our downside scenario. The model range is unusually wide ($12.90 to $36.51). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Key figures of Crescent Capital BDC Inc
How large is the market capitalisation of Crescent Capital BDC Inc (CCAP)?
The market capitalisation of Crescent Capital BDC Inc is $346M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Crescent Capital BDC Inc (CCAP)?
The price-to-sales ratio of Crescent Capital BDC Inc is 2.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Crescent Capital BDC Inc (CCAP)?
Earnings per share at Crescent Capital BDC Inc are $−0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Crescent Capital BDC Inc (CCAP)?
The net margin of Crescent Capital BDC Inc is −2.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Crescent Capital BDC Inc (CCAP)?
The return on equity (ROE) of Crescent Capital BDC Inc is −0.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Crescent Capital BDC Inc (CCAP)?
On an EBIT basis the return on assets of Crescent Capital BDC Inc is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Crescent Capital BDC Inc (CCAP)?
The operating margin of Crescent Capital BDC Inc is 78.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Crescent Capital BDC Inc (CCAP)?
Revenue at Crescent Capital BDC Inc is growing −15.5% versus a year earlier (3y avg +44.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Crescent Capital BDC Inc (CCAP)?
Earnings per share at Crescent Capital BDC Inc are growing −14.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Crescent Capital BDC Inc (CCAP) carry?
The net debt of Crescent Capital BDC Inc is $842M (fiscal year 2025, ≈ 11.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Crescent Capital BDC Inc in the live analysis
One click puts Crescent Capital BDC Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026